Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

158.02 +2.72 (+1.75%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,678,823
Open 155.28
Bid (Size) 157.50 (2)
Ask (Size) 158.24 (1)
Prev. Close 155.30
Today's Range 154.59 - 158.48
52wk Range 134.09 - 175.91
Shares Outstanding N/A
Dividend Yield 3.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
It isn't an easy decision to choose the best among this group of dividend stocks. 
Via The Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
These pharma giants beat the bear market last year. 
Via The Motley Fool

Performance

YTD
-2.69%
-2.69%
1 Month
+3.91%
+3.91%
3 Month
-3.05%
-3.05%
6 Month
+11.90%
+11.90%
1 Year
-2.05%
-2.05%

More News

Read More
This Delivery Giant Is A 'Comeback Story' Plus Nike, AbbVie And Oracle: CNBC's 'Final Trades'
Via Benzinga
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
Via The Motley Fool
2 Reasons to Buy AbbVie, and 1 Reason to Sell
Via The Motley Fool
Price Over Earnings Overview: AbbVie
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
Use These 3 Strategies to Make $1,000 in Passive Income Per Year
Via The Motley Fool
AbbVie Provides Regulatory Update On Parkinson's Disease Drug Candidate
Via Benzinga
These 3 Dividend Growers Yield More Than the 10-Year Note
Via MarketBeat
Topics Bonds
Exposures Debt Markets
4 Top Value Stock ETFs for Long-Term Wealth Building
Via The Motley Fool
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
2 Growth Stocks to Buy Before the Bull Market Arrives
Via The Motley Fool
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Via Benzinga
Healthcare Stocks With at Least 30 Years of Dividend Increases
Via MarketBeat
Oracle, AbbVie And This Gold Fund: CNBC's 'Final Trades'
Via Benzinga
Dividend Income Update February 2023
Via Talk Markets
5 Forever Dividend Stocks
Via The Motley Fool
Diversify Your Income with These 2 High-Yielding Dividend ETFs
Via MarketBeat
Topics ETFs
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in March
Via The Motley Fool
Reap Monthly Income With This Combination Of 3 Stocks
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.